GlassScriptPhysician profile
Josephine Doo
NPI 1336670116
$9,360.85
in general payments reported to CMS, 2019-2025
15 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $280 · 2023: $3,777 · 2024: $4,579 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,725 · Food and Beverage: $3,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,724.90 |
| Food and Beverage | $3,049.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,132.64 | 2022-2025 | Solyx Sis System, Advantage System, Upsylon |
| Axonics, INC. | $3,106.53 | 2022-2024 | Axonics, Bulkamid |
| Coloplast Corp | $1,939.17 | 2021-2025 | Altis |
| Medtronic, INC. | $288.81 | 2021-2024 | Interstim |
| Astellas Pharma US INC | $170.29 | 2024 | Veozah |
| Abbvie INC. | $145.97 | 2023-2025 | Botox, Orilissa |
| Palette Life Sciences, INC. | $135.42 | 2022 | |
| Caldera Medical, INC | $134.40 | 2023 | Desara |
| Urovant Sciences INC | $84.67 | 2022 | |
| Mayne Pharma Commercial LLC | $48.49 | 2025 | |
| Lilly USA, LLC | $44.60 | 2025 | Zepbound, Mounjaro |
| Acella Pharmaceuticals, LLC | $39.61 | 2024-2025 | NP Thyroid 60 |
| Sumitomo Pharma America, INC. | $36.69 | 2025 | Gemtesa |
| Bluewind Medical | $31.28 | 2025 | Revi |
| Laborie Medical Technologies Corp. | $22.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Doo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.